Obsessive-compulsive disorder is characterized by the presence of either obsessions or compulsions, but more commonly by both symptoms that can cause marked impairment or distress.
Obsession is a recurrent, persistent, intrusive, unwanted thought, image or urge that cause distressing emotions (eg anxiety and disgust).
Compulsion is a repetitive behavior or mental act that the person feels driven to perform, in order to lessen the distress caused by the obsession.
Anxiety is the central feature of obsessive-compulsive disorder.
More than three-fourths of people with mood, anxiety and alcohol use disorder in Singapore receive no treatment for their condition, reflecting a high treatment gap in mental healthcare that has remained a matter of concern for years now, according to data from the 2016 Singapore Mental Health Study.
Individuals with obsessive–compulsive disorder (OCD) with a chronic illness course are at greater risk of remaining chronic, which, in turn, is associated with poor clinical outcome, according to a study.
Malignant obsessive–compulsive disorder (OCD) has a poor long-term prognosis, a study suggests. Moreover, patients who undergo neurosurgical treatment with capsulotomy may require psychiatric treatment and psychotropic medication many years after the procedure.
There are different patterns of subcortical abnormalities in paediatric and adult patients with obsessive-compulsive disorder (OCD), with the pallidum and hippocampus appearing to be of importance in adult OCD and the thalamus in paediatric OCD, according to results of meta- and mega-analyses.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.